Why the study?
Does commercial TTVR improve hemodynamics and clinical outcomes in high-risk patients with severe tricuspid regurgitation?
Observational (n=1,034)
Yes
Does commercial TTVR improve hemodynamics and clinical outcomes in high-risk patients with severe tricuspid regurgitation?
Commercial TTVR demonstrates high technical success, significant TR reduction, and acceptable safety at 30 days in a high-risk, real-world population.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Anamika et al. (2026) conducted an observational in Severe tricuspid regurgitation (n=1,034). Commercial TTVR was evaluated on Technical success, residual TR reduction, and adverse events (mortality, stroke, bleeding, CIED requirement).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: